All In Biotech

Drug Trial Radar · NCT07354074

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

A Phase II, Multicenter, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Asciminib in Pediatric Participants Newly Diagnosed or Previously Treated With Philadelphia Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) With or Without Known T315I Mutation

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Apr 28, 2026

Primary completion

Feb 23, 2033

Study completion Feb 23, 2033

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to support development of asciminib in the pediatric population (1 to \< 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose, fed state) or adult formulation (fasted) in newly diagnosed and resistant or intolerant Ph+ CML-CP with or without T315I mutation.

Conditions

  • Chronic Myelogenous Leukemia
  • Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive

Interventions

  • Asciminib single agentDrug

    Asciminib (labelled as ABL001) administered as 40 mg tablet (adult formulation) or as 1 mg film-coated granules mini-tablets (pediatric formulation)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MMR at Week 48Time frame: 48 weeks

Locations

39 sites in 17 countries. Site status is shown where the registry gives one.

  • Ann and Robert H Lurie Childs Hosp

    Chicago, Illinois · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • Columbia University Medical Center New York Presbyterian

    New York, New York · Recruiting

  • Cinn Children Hosp Medical Center

    Cincinnati, Ohio · Recruiting

  • Seattle Childrens Hospital

    Seattle, Washington · Recruiting

  • Novartis Investigative Site

    Brisbane, Queensland, Australia · Recruiting

  • Novartis Investigative Site

    North Adelaide, South Australia, Australia · Recruiting

  • Novartis Investigative Site

    Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting

  • Novartis Investigative Site

    Barretos, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    Edmonton, Alberta, Canada · Recruiting

  • Novartis Investigative Site

    Montreal, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Tianjin, China · Recruiting

  • Novartis Investigative Site

    Zhengzhou, Henan, China · Recruiting

  • Novartis Investigative Site

    Marseille, France · Recruiting

  • Novartis Investigative Site

    Paris, France · Recruiting

  • Novartis Investigative Site

    Poitiers, France · Recruiting

  • Novartis Investigative Site

    Strasbourg, France · Recruiting

  • Novartis Investigative Site

    Erlangen, Germany · Recruiting

  • Novartis Investigative Site

    Hamburg, Germany · Recruiting

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, Germany · Recruiting

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, Hungary · Recruiting

  • Novartis Investigative Site

    Padova, PD, Italy · Recruiting

  • Novartis Investigative Site

    Roma, RM, Italy · Recruiting

  • Novartis Investigative Site

    Fukuoka, Japan · Recruiting

  • Novartis Investigative Site

    Saitama, Japan · Recruiting

  • Novartis Investigative Site

    Yokohama, Kanagawa, Japan · Recruiting

  • Novartis Investigative Site

    Utrecht, Netherlands · Recruiting

  • Novartis Investigative Site

    Gdansk, Poland · Recruiting

  • Novartis Investigative Site

    Wroclaw, Poland · Recruiting

  • Novartis Investigative Site

    Singapore, Singapore · Recruiting

  • Novartis Investigative Site

    Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

  • Novartis Investigative Site

    Bangkok, Thailand · Recruiting

  • Novartis Investigative Site

    Bangkok, Thailand · Recruiting

  • Novartis Investigative Site

    Hanoi, Vietnam · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.